Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

J&J Seeks Command Position In FcRn Space With Momenta Buyout

Aug 19 2020

• By Joseph Haas

Johnson_and_Johnson — J&J will pay $6.5bn to buy out Momenta and its anti-FcRn candidate

Related Content

UCB Pushes On With Potential Myasthenia Gravis Therapy, But Competition Looms

Oct 18 2018

Momenta Refocuses On Three Novel Autoimmune Drugs In Transition To More Traditional Biotech

Oct 02 2018

Impressive Clinical Results For Argenx’s Oncology Candidate Seal The Deal for Janssen

Dec 03 2018

Alexion Continues Pipeline Rebuilding With $400m Takeout Of Syntimmune

Sep 26 2018

Roivant Unveils An Autoimmune-Focused 'Vant' At Inaugural Pipeline Day

Jul 11 2018

Argenx Builds Presence As Efgartigimod Positive In Pivotal Myasthenia Study

May 27 2020

Strategic M&A: Sanofi Buys Principia Biopharma For $3.7bn

Aug 17 2020

Related Companies

Johnson & Johnson

Momenta Pharmaceuticals, Inc.

argenx N.V.

Janssen-Cilag International

Regeneron Pharmaceuticals, Inc.

Viatris Inc.

Principia Biopharma, Inc.

Immunovant, Inc.

Roivant Sciences Ltd.

UCB S.A.

Alexion Pharmaceuticals Inc.

Syntimmune, Inc.

Affibody AB

Additional Topics

M & A Deals Business Strategies Commercial Immune Disorders BioPharmaceutical

More from Deals

More from Business

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window